Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 120, Issue 4, Pages 5010-5017Publisher
WILEY
DOI: 10.1002/jcb.27776
Keywords
antigenic targets; chimeric antigen receptors (CARs); gastric adenocarcinoma; immunotherapy
Categories
Funding
- Tehran University of Medical Sciences, Digestive Disease Research Institute [301/579]
Ask authors/readers for more resources
Gastric adenocarcinoma is usually diagnosed in late stages, necessitating the use of different therapeutic modalities. Currently, antibody-based therapies have also been approved through with limited clinical efficacy. Reinforcing antibody-based immunotherapy by using chimeric antigen receptor (CAR) T cells may enhance the approach. However, the cells can cause severe on-target and off-tumor toxicities owing to their higher sensitivity to low-level antigen expressions. To address the need for safe and reliable targets, we made a bioinformatics pipeline by which we screened overexpressed genes in the disease for off-tumor sites in many normal tissues. Our inspection showed that MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the probable targets of CAR T cell therapy in gastric adenocarcinoma. The proposed antigenic targets might respond to the need to simultaneously target multiple antigens in a tumor matrix to prevent resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available